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Abstract 
Objective: The human vitamin E-binding glycoprotein afamin is primarily expressed in 
liver and has been associated with prevalent and incident metabolic syndrome. These 
data were in line with observations in transgenic mice. We thus investigated whether 
afamin concentrations are associated with prediabetes, type 2 diabetes, and insulin 
resistance. 
Research Design and Methods: Individual-level baseline (n=20,136) and follow-up 
data (n=14,017) of 8 prospective cohort studies were investigated. Study-level data 
were combined using random-effects meta-analyses. Main outcomes were prevalent 
and incident type 2 diabetes, prediabetes, and insulin resistance. Discrimination and 
reclassification of participants was analysed for incident type 2 diabetes. 
Results: Mean afamin concentrations between studies ranged from 61-73 mg/L. The 
eight studies included 1,398 prevalent and 585 incident cases of type 2 diabetes. Each 
increase of afamin by 10 mg/L was associated with prevalent type 2 diabetes: OR=1.19 
(95%CI 1.12-1.26), p=5.96x10-8. Afamin was positively associated with insulin 
resistance assessed by HOMA-IR: ß=0.110 (95%CI 0.089-0.132), p=1.37x10-23. Most 
importantly, afamin measured at baseline was an independent predictor for 585 
incident type 2 diabetes cases: OR=1.30 (95%CI 1.23-1.38), p=3.53x10-19 and showed 
a significant and valuable gain in risk classification accuracy when added to this 
extended adjustment model. 
Conclusions: This pooled analysis in more than 20,000 individuals showed that 
afamin is strongly associated with insulin resistance, prevalence and incidence of type 
2 diabetes independent of major metabolic risk factors or parameters. Afamin might be 
a promising novel marker for the identification of individuals at high risk for the 
development of type 2 diabetes. 
 
 
  
 3 
The worldwide number of adults with type 2 diabetes has quadrupled during the last 
35 years. In 2014, the age-standardized prevalence rate was 9.0% for men and 7.9% 
for women, and is predicted to increase to 12.8% and 10.8%, respectively, by 2025 
(1). Most importantly, about a third to a half of individuals with diabetes mellitus remains 
undiagnosed (2,3). Besides the enormous annual costs of 825 billion dollars 
worldwide, metabolic syndrome and diabetes mellitus increase subsequent non-fatal 
and fatal outcomes (2,4,5). More than 2 million deaths every year can be attributed to 
diabetes mellitus and its macrovascular and microvascular complications (1). Thus, an 
in-depth understanding of the pathogenesis as well as the identification of early risk 
predictors is of major importance. 
We recently demonstrated in a pooled analysis of three epidemiological studies 
including more than 5,000 study participants that plasma afamin concentrations are 
predictive not only for the prevalence but also for the incidence of metabolic syndrome 
(6). In patients with polycystic ovary syndrome afamin concentrations have been 
reported to be associated with insulin resistance (7), but data on the association 
between afamin and type 2 diabetes are still lacking. 
Afamin was first described in 1994 as the fourth member of the human albumin 
gene family including albumin, -fetoprotein and vitamin D-binding protein (8,9). The 
human plasma glycoprotein afamin has a molecular mass of 87 kD with 15% 
carbohydrate content (10) and 55% amino acid sequence similarity to albumin (8). It is 
primarily expressed in the liver (8) but also in tissues such as brain, testes, ovaries and 
kidney (www.proteinatlas.org). Knowledge about the (patho-)physiological functions of 
this protein is still limited (11,12). Transgenic mice overexpressing the human afamin 
gene developed increased body weight and increased blood concentrations of lipids 
and glucose (6). Based on these findings and the epidemiological data on afamin and 
metabolic syndrome in humans (6), we aimed to investigate, whether afamin is 
associated with the prevalence and incidence of type 2 diabetes in a pooled analysis 
in more than 20,000 individuals from mainly population-based cohorts. Furthermore, 
we evaluated whether afamin is also related to prediabetes and type 2 diabetes-related 
phenotypes such as insulin resistance. 
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Research Design and Methods 
Study Populations and Study Design 
This investigation is based on eight prospective cohort studies, six of them were 
per definition population-based (Bruneck, KORA F3, KORA F4, CoLaus, YFS, and the 
NHLBI Family Heart Study), one study included unrelated healthy middle-aged men 
from nine general practices (NPHS-II), and one study was based on a healthy working 
population (SAPHIR). The baseline examination included a total of 20,136 individuals 
and from 14,017 individuals a follow-up examination was available. The baseline 
examination finally included a total of 20,094 individuals for prevalent and the follow-
up examination 13,347 individuals for incident type 2 diabetes, respectively. 
Percentage of loss to follow-up varied between 3% (NPHS-II) and 36% (NHLBI Family 
Heart Study). This frequency could not be calculated for the CoLaus Study since 
follow-up collection of data on incident diabetes is still work in progress. The average 
follow-up time in the eight studies ranged from 4.5 to 12.5 years (Supplementary Table 
1). All studies were approved by the respective local ethics committees. Clinical 
investigations described were carried out according to the Declaration of Helsinki. All 
participants provided written informed consent. For more details on study design, 
recruitment, clinical assessment of laboratory parameters and definition of outcomes 
see Supplementary Material. 
Definition of outcomes 
Type 2 diabetes was defined either as self-reported, and/or as fasting glucose 
≥126 mg/dL, (≥7 mmol/L) according to the 1997 American Diabetes Association (ADA) 
criteria (13) and/or receiving anti-diabetic medication. Participants with diagnosis of 
type 1 diabetes were excluded. More details on the specific definitions in each study 
can be found in the Supplementary Material. 
Measures of insulin resistance such as homeostasis model assessment-
estimated insulin resistance (HOMA-IR) and whole-body insulin sensitivity index 
(ISI(composite)) were calculated as described in the Supplementary Material. 
Prediabetes was specified according to the 1997 ADA definition (impaired fasting 
glucose defined as fasting glucose of ≥100-125 mg/dL (≥5.6-6.9 mmol/L) and impaired 
glucose tolerance as 2-h glucose value between ≥140-199 mg/dL (≥7.8-11.0 mmol/L)) 
(13).  
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Measurement of afamin plasma concentrations 
Afamin was quantified with a custom-made double-antibody sandwich ELISA as 
previously described (6,10,14,15). Within-run and between-run coefficients of variation 
were 3.3% and 6.2%, respectively (15). Afamin concentrations were measured in all 
studies in the laboratory at the Medical University of Innsbruck. Extended information 
on the quality control of lab work is given in the Supplementary Material. 
Statistical analyses in all cohorts 
At baseline, the association between afamin and prevalent type 2 diabetes was 
explored by logistic regression analysis. At the follow-up investigation, logistic 
regression modelling of the relation of afamin values measured at baseline with 
incident type 2 diabetes was performed and participants with type 2 diabetes at 
baseline were excluded. Because exact dates of diagnosis of type 2 diabetes were not 
known in all studies, logistic instead of Cox proportional hazard regression was used 
for investigating incident type 2 diabetes. Both prevalent and incident type 2 diabetes 
were considered as primary outcomes. All further analysed outcomes (fasting insulin 
and glucose concentrations, glycated hemoglobin (HbA1c), HOMA-IR, whole-body 
ISI(composite) (in KORA F4 only)) were considered as secondary outcomes. For all 
analyses done, the first model was adjusted for age and sex and the second (referred 
to as extended adjustment model) additionally for other potential major metabolic risk 
factors or parameters (HDL cholesterol, triglycerides, BMI, hypertension and in 6 out 
of 8 studies glucose concentrations).  
The linearity of afamin on all outcomes was tested by a penalized, age- and sex-
adjusted regression spline approach in the large population-based in-house KORA F4 
Study that served as a reference for all other studies included in the pooled analyses. 
In addition, results for afamin divided into quartiles are shown for primary outcomes.  
Afamin concentrations are quite normally distributed (6). Whole-body 
ISI(composite), further continuous type 2 diabetes-related phenotypes (fasting insulin 
and glucose concentrations, HbA1c, HOMA-IR) and triglycerides were log-transformed 
based on the natural logarithm (ln) due to their skewed distribution. 
To test heterogeneity between study-specific beta estimates, I2 index as well as 
chi-square based Q-statistic was calculated for each outcome according to the age- 
and sex-adjusted model (16). Since there was an indication for heterogeneity for 
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prevalent diabetes (one of the two main outcomes) (Supplementary Table 2), a pooled 
effect size for the respective studies was calculated using random effects meta-
analysis according to (17).  
Further specific statistical analyses in the KORA F4 Study  
For the primary outcome incident diabetes, both a model additionally including 
glucose concentrations ≥100 mg/dL (100-125 mg/dL vs. <100 mg/dL=reference) 
beside major metabolic risk factors or parameters and a model considering glucose 
concentrations ≥100 mg/dL and family history of diabetes was calculated. This cut-off 
of ≥100 mg/dL for glucose concentrations was defined according to the 1997 ADA 
definition for impaired fasting glucose (IFG) (13). 
Family history of diabetes in KORA F4 included information about diabetes for all 
first grade relatives and took age of onset into account (18). Variable selection in both 
adjustment models was based on the Framingham Risk Score for type 2 diabetes (19). 
Furthermore, logistic regression analyses were performed on the association of afamin 
with prediabetes and linear regression analyses on the association with whole-body 
ISI(composite). These latter analyses on whole-body ISI(composite) as well as linear 
regression models on further continuous type 2 diabetes-related phenotypes described 
above (fasting insulin and glucose concentrations, glycated hemoglobin (HbA1c), 
HOMA-IR) were calculated excluding participants with prevalent type 2 diabetes at 
baseline. HOMA-IR and whole-body ISI(composite) were also analysed divided by a 
cut-off of 2.5.  
We considered incident type 2 diabetes as outcome also taking an oral glucose 
tolerance test (OGTT) into account and performed a test of deviances on nested 
models to assess whether afamin significantly added to the extended adjustment 
model. Whether afamin concentrations contributed to a better classification of 
individuals into predefined categories of incident type 2 diabetes risk in addition to a 
model already including major metabolic risk factors or parameters (age, sex, HDL 
cholesterol, triglycerides, BMI, hypertension and 1) fasting glucose concentrations 
≥100 mg/dL (100-125 mg/dL vs. <100 mg/dL=reference) or 2) fasting glucose 
concentrations ≥100 mg/dL (100-125 mg/dL vs. <100 mg/dL=reference) and family 
history of diabetes was also evaluated. The categorical net reclassification 
improvement (NRI) was calculated using the reclass function in R based on the 
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following risk categories (<5%, 5-24% and >=25%) for individuals who developed type 
2 diabetes during a median follow-up of 6.4 years (n=132) and for those who did not 
receive a diagnosis of type 2 diabetes (n=1,718) as well as for the total group. Standard 
errors for categorical NRI were computed according to Pencina et al. (20). For 
comparison purposes the continuous NRI was also calculated (again for cases and 
controls as well as the total group) with the function improveProb in R. The continuous 
NRI has the advantage over the categorical NRI that it does not depend on the choice 
of specific risk categories, and any change in predicted risk in the correct direction is 
considered appropriate.  
For all analyses performed, a two-sided test P-value <0.05 was considered 
statistically significant. Analyses were performed using SPSS for Windows, version 
21.0 (IBM Corp., Armonk, New York, NY, USA) and R for Windows, version 3.1.3 
(Vienna, Austria). 
 
Results 
Baseline characteristics 
Baseline characteristics of all eight studies included in this pooled analysis are 
shown in Supplementary Table 1. Mean afamin concentrations were lowest in the 
Young Finns Study (61.4±15.4 mg/L), and highest in the CoLaus Study (73.1±16.6 
mg/L). Based on nonlinear P-splines there was no evident deviation from linearity of 
afamin in the applied regression models neither at baseline nor at follow-up in KORA 
F4 (Supplementary Figures 1 to 6). There was no effect of sex on associations of 
afamin with main outcomes (data not shown). 
Association between afamin concentrations and prevalent type 2 diabetes 
(primary outcome) 
The age- and sex-adjusted logistic regression analysis revealed an increased 
probability for prevalent type 2 diabetes per 10 mg/L increase in afamin concentrations 
(OR=1.40, 95%CI 1.31-1.48, p=2.54x10-27). The extended model was additionally 
adjusted for HDL cholesterol, triglycerides, BMI and hypertension and still showed an 
OR=1.19, 95%CI 1.12-1.26, p=5.96x10-08 (Figure 1, panel A and Supplementary Table 
3). When afamin was categorized in quartiles, the association reached statistical 
significance in the age- and sex-adjusted model when the third and the fourth quartile 
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were compared to the first quartile (OR=1.74, 95%CI 1.38-2.20, p=3.47x10-6 and 
OR=3.91, 95%CI 2.97-5.14, p=2.10x10-22, respectively). This association was still 
significant for the fourth quartile after extended adjustment (OR=1.72, 95%CI 1.27-
2.33, p=5.09x10-4) (Figure 1, panel B, and Supplementary Table 4). In a sensitivity 
analysis we excluded the studies KORA-F3 and NPHSII from the pooled analysis since 
their participants were not necessarily fasting. This reduced heterogeneity, but led 
basically to the same results with slightly increased effect estimates. 
Association between afamin concentrations and incident type 2 diabetes 
(primary outcome) 
Afamin concentrations measured at baseline were also a significant predictor for 
the development of type 2 diabetes during follow-up. Each increase in afamin 
concentrations by 10 mg/L was significantly associated with a 49% higher odds for 
incident type 2 diabetes (OR=1.49, 95%CI 1.42-1.56, p=5.97x10-62) in the age- and 
sex-adjusted model and with a 30% higher odds in the extended adjustment model 
(OR=1.30, 95%CI 1.23-1.38, p=3.53x10-19) (Figure 2 panel A and Supplementary 
Table 3). When afamin concentrations were stratified in quartiles the association was 
most pronounced for the fourth quartile with an OR of 5.28 (95%CI 3.83-7.27, 
p=2.64x10-24) in the age- and sex-adjusted model and an OR of 2.33 (95%CI 1.61-
3.36, p=6.66x10-6) in the extended adjustment model. This association was already 
present but less pronounced in the third quartile (age- and sex-adjusted: OR=2.56, 
95%CI 1.88-3.49, p=2.25x10-9; extended adjustment model: OR=1.47, 95%CI 1.04-
2.08, p=0.03) (Figure 2 panel B and Supplementary Table 5). Again, excluding KORA-
F3 and NPHSII revealed similar results with slightly increased effect estimates. 
Association between afamin concentrations and continuous type 2 diabetes-
related phenotypes (secondary outcomes) 
Further analyses on continuous type 2 diabetes-related phenotypes such as 
HbA1c, insulin, glucose and HOMA-IR were performed excluding all participants who 
already had type 2 diabetes at baseline. Baseline afamin concentrations were 
positively associated with insulin concentrations and HOMA-IR in the age- and sex-
adjusted as well as in the extended adjustment model (Table 1 and Supplementary 
Table 6). An example of a forest plot is provided for HOMA-IR in Supplementary Figure 
7. These associations were less pronounced but still statistically significant in both 
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adjustment models for glucose and HbA1c as dependent variables (Table 1 and 
Supplementary Table 6). 
 
Extended analyses in the KORA F4 Study 
Association between afamin and prediabetes as well as insulin resistance 
Each increase of age- and sex-adjusted plasma afamin concentrations by 10 
mg/L increased the probability for prediabetes based on the 1997 ADA definition in 
2,635 KORA F4 individuals without type 2 diabetes at baseline: OR=1.41, 95%CI 
(1.33-1.49), p=1.66x10-29. The same was observed for the extended adjustment 
model: OR=1.21, 95%CI (1.14-1.30), p=8.62x10-09.  
Besides these findings afamin was inversely related to insulin resistance based 
on whole-body insulin sensitivity index (ISI(composite)) in both adjustment models in 
the KORA F4 Study (Table 1). When this insulin resistance measure was stratified by 
a cut-off of 2.5, each increase in afamin concentrations by 10 mg/L was associated 
with an increased probability for insulin resistance (OR=1.89, 95%CI 1.67-2.15, 
p=3.92x10-23). This association remained highly significant in the extended-adjustment 
model (OR=1.77, 95%CI 1.54-2.03), p=6.94x10-16). The same association was found 
for HOMA-IR stratified by 2.5: each increase in afamin concentrations by 10 mg/L was 
related to a higher probability for insulin resistance in the age- and sex-adjusted model 
(OR=1.70, 95%CI 1.58-1.82, p=5.91x10-91) and extended adjustment model 
(OR=1.47, 95%CI 1.34-1.56, p=1.45x10-20), respectively. 
Association between afamin and incident type 2 diabetes based on variable 
selection according to the Framingham Risk Score for type 2 diabetes 
Further adjustment models on the development of type 2 diabetes were done. 
When fasting glucose concentrations ≥100 mg/dL (100-125 mg/dL vs. <100 
mg/dL=reference) were additionally included in the extended adjustment model, 
afamin concentrations measured at baseline were still a significant predictor for the 
development of type 2 diabetes (OR=1.35, 95%CI 1.17-1.57, p=6.19x10-5). When all 
cohorts were taken into account where fasting plasma glucose concentrations were 
available, pooled effect estimates for afamin in these 6 studies did only marginally differ 
when compared to the single analysis in KORA F4 (with glucose concentrations as 
categorical variable (100-125 mg/dL vs. <100 mg/dL=reference) (OR=1.27, 95%CI 
 10 
1.18-1.36, p=5.09*10-10). Furthermore, when glucose concentrations were included in 
the model on a continuous scale, the effect estimate was almost unchanged (OR=1.21, 
95%CI 1.11-1.30, p=2.87x10-6) (for more details see Supplementary Table 7). 
Even when besides glucose concentrations ≥100 mg/dL family history of diabetes 
was taken into account, each increase in afamin concentrations by 10 mg/L still 
showed a significantly higher probability for incident type 2 diabetes (OR=1.33, 95%CI 
1.13-1.56, p=0.001).  
Various further adjustment models for primary and secondary outcomes were 
done. No matter if we added either smoking, alcohol intake, physical activity, waist 
circumference (instead of BMI), family history of diabetes, fasting glucose 
concentrations, fasting insulin concentrations, or HOMA-IR (where appropriate) to the 
extended adjustment model, effect estimates of afamin remained highly significant 
(range of OR 1.20 to 1.43, all p values ≤0.001). Similar results were found for type 2 
diabetes-related phenotypes which did not show major changes in the beta estimates 
for all outcomes (data not shown). 
Afamin and type 2 diabetes risk discrimination and reclassification analysis  
To assess whether afamin contributes to a better discrimination between 
individuals who developed type 2 diabetes and those who remained free of type 2 
diabetes during the prospective follow-up in the KORA F4 Study, two statistical 
concepts were applied: 1) deviances and 2) categorical as well as continuous net 
reclassification index (NRI). For these analyses we applied a more accurate definition 
for incident type 2 diabetes available in KORA F4 further using an oral glucose 
tolerance test (OGTT) (according to the 1997 ADA criteria) (13).  The effect estimate 
of afamin did not change compared to the diabetes definition without OGTT as used in 
the pooled analysis according to the extended adjustment model (OR=1.48, 95%CI 
1.32-1.66, p= 5.96*10-11 vs. OR=1.40, 95%CI 1.23-1.60, p=5.49*10-7). The model 
including afamin (deviance= 694.69) showed a significantly improved model fit 
compared to the extended risk model including glucose concentrations ≥100 mg/dL 
(100-125 mg/dL vs. <100 mg/dL=reference) (deviance= 726.90) (difference in 
deviance -32.21, p<0.0001). When besides glucose concentrations ≥100 mg/dL family 
history of diabetes was additionally included in the extended adjustment model 
(deviance= 602.71), the model also containing afamin (deviance= 577.07) still 
indicated a significantly improved model fit (difference in deviance -25.64, p<0.0001). 
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Furthermore, the categorical NRI was applied to test whether inclusion of afamin into 
a model containing known metabolic risk factors or parameters significantly adds to 
type 2 diabetes risk reclassification. Based on predefined risk categories (<5%, 5-24%, 
≥25%), as shown in Table 2, NRI for cases was 0.114 (95%CI 0.031-0.221), p=0.002 
and for controls 0.021 (95%CI 0.006-0.036), p=0.008. Overall NRI for the total group 
was 0.135 (95%CI 0.048-0.221, p=0.002). Of the 132 individuals who developed type 
2 diabetes, 24 (18.2%) were correctly reclassified and thus moved to a higher risk 
category. Of those who remained free of type 2 diabetes (n=1,718), 110 (6.4%) moved 
to a lower risk category and can be considered as correctly reclassified based on 
adding afamin to the risk model. In subjects at intermediate risk (5% to <24%), the 
addition of afamin to the risk model resulted in a correct reclassification of 17 cases 
(24.3%) and 84 controls (19.9%), respectively (Table 2 and Supplementary Figure 8). 
Even when additionally adding family history of diabetes to the risk model, afamin still 
contributed to an improved type 2 diabetes risk reclassification (see Supplementary 
Table 8 and Supplementary Figure 9). Results based on continuous NRI showed a 
significant gain in classification accuracy when afamin was added to the risk model: 
NRI for cases 0.197 (95%CI: 0.030-0.364) p=0.02, and for controls 0.354 (95%CI 
0.310-0.398) p<0.0001. Overall continuous NRI for the total group was 0.551 (95%CI: 
0.378-0.724), p<0.0001. This means that in about three of five subjects the assignment 
to the case or control status has been enforced by adding afamin to the risk model. 
The same conclusion holds true when also family history of diabetes was included in 
the risk classification calculations because absolute NRI values did not change for NRI 
for the total group 0.491 (95%CI: 0.298-0.685), p<0.0001 and NRI for controls 0.351 
(95%CI: 0.305-0.398), p<0.0001, and were only slightly attenuated for NRI for cases 
0.140 (95%CI: 0.047-0.328), p=0.14).  
 
Conclusions  
This is the first analysis in more than 20,000 individuals from mainly population-
based studies that describes novel associations of afamin with prevalent and incident 
type 2 diabetes and type 2 diabetes-related phenotypes. The main findings were: 1) 
increased afamin concentrations were significantly associated with prediabetes and 
type 2 diabetes at baseline and type 2 diabetes-related phenotypes such as insulin 
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resistance defined by HOMA-IR and whole-body ISI(composite). 2) Afamin 
concentrations at baseline significantly predicted the development of type 2 diabetes 
during follow-up. All these associations were independent from major metabolic risk 
factors or parameters. 3) Afamin showed a significant improved model fit and gain in 
classification accuracy for incident type 2 diabetes when added to an extended 
adjustment model including major metabolic risk factors or parameters. 
Previously, we showed that afamin concentrations measured at baseline were 
significantly related to all components of the metabolic syndrome, with one of the 
strongest associations found with elevated waist circumference at both the baseline 
and follow-up investigation (6). Elevated waist circumference and BMI are measures 
of increased body fat and well-established risk factors for the metabolic syndrome and 
type 2 diabetes (21-23). Furthermore, this increase in body fat elevates not only the 
risk for type 2 diabetes but also for insulin resistance. Most importantly, in our large 
analysis afamin was associated with prediabetes, measures of insulin resistance as 
well as the prevalence and incidence of type 2 diabetes independently of major 
metabolic factors or parameters. Taken together, the findings on incident type 2 
diabetes and prediabetes strongly suggest that afamin might be a valid marker to 
predict a high risk for developing type 2 diabetes. Novel mechanisms and pathways 
besides those related to metabolic syndrome might be involved. 
Adipose tissue can affect the development of insulin resistance in other tissues 
such as liver by producing free fatty acids and several other pro- and anti-inflammatory 
factors (24). Insulin resistance causes hyperinsulinemia and leads to steatosis via 
various mechanisms such as increased hepatic de novo lipogenesis (24), 
inflammation, and lipotoxicity (25). There is evidence that non-alcoholic fatty liver 
disease might also be a risk factor for future type 2 diabetes and not only vice versa 
(26). As afamin is primarily expressed in liver, the liver might indeed play an important 
role in contributing to elevated afamin concentrations and thus development of type 2 
diabetes. 
In general, afamin seems to have heterogeneous effects depending on the site 
of action. It has been shown that afamin might have binding properties for two of the 
major forms of anti-oxidative vitamin E, α-tocopherol and γ-tocopherol (14). The anti-
oxidative function of vitamin E remains controversial (27). Our previous work has 
demonstrated that plasma afamin concentrations are not associated with those of 
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vitamin E, indicating that afamin does not play a major role in binding and transporting 
vitamin E in plasma (in fact, vitamin E is mostly carried by the lipoprotein system) (10). 
Thus, the proposed vitamin E binding role of afamin might be of functional relevance 
for diseases such as type 2 diabetes and metabolic syndrome only in extravascular 
fluids or tissues. Possible mechanisms for such a scenario remain unknown. 
The causality of afamin’s association with type 2 diabetes as well as possible 
underlying mechanisms remains to be elucidated. The preliminary findings of a 
hyperglycemic phenotype in mice transgenic for the human afamin gene are supportive 
for a causal role of afamin for the development of type 2 diabetes (6). A direct role of 
afamin in glucose metabolism was very recently shown by Shen et al. in a thyroid 
carcinoma cell line transfected with human afamin (28). Afamin was found to 
upregulate several key enzymes and metabolites of glucose metabolism revealing new 
possible insights into the molecular functions of afamin. Since the transgenic animals 
as well as the transfected cell line model are of only limited relevance for the 
pathogenesis of type 2 diabetes in humans, both models have to be considered with 
caution as valid models for a functional and causal role of afamin in type 2 diabetes. 
Our results are in accordance with a recently reported study demonstrating a 
strong association between concentrations of microRNA-122 (miRNA-122), and the 
incidence for metabolic syndrome and type 2 diabetes in the Bruneck Study (29). 
MiRNA-122 was also highly significantly associated with afamin analysed by 
proteomics approach. MiRNAs play a key role in the epigenetic regulation of gene 
expression. MiRNA-122 is the predominant miRNA in liver and regulates a number of 
genes involved in cholesterol and fatty acid metabolism (for review, see (30). Willeit et 
al. therefore investigated in a mouse model the expressed hepatic proteome after 
antisense targeting of miRNA-122. Afamin was not differentially expressed when 
comparing untreated mice with mice lacking miRNA-122 suggesting no gene 
regulatory function of miRNA-122 for afamin at least in mice (29). 
Finally, the question remains whether afamin adds information to well-known risk 
predictors for incident type 2 diabetes. All measures of discrimination and 
reclassification, i.e. deviance, continuous and categorical NRI, suggested a significant 
and valuable gain in model fit and classification accuracy in the population-based 
KORA F4 Study when afamin measured at baseline was added to a risk model 
including age, sex, metabolic risk factors or parameters, glucose concentrations ≥100 
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mg/dL and a positive family history of diabetes. This is even more impressive as most 
of these metabolic risk factors or parameters are major components of the metabolic 
syndrome.  
A main strength of the study is that data were generated from eight independent 
populations, the great majority of them being population-based. In addition, we had 
follow-up data on incident type 2 diabetes available in all of these studies. It might be 
considered as a limitation that we performed the extended analyses and adjusted for 
potential confounders or risk factors such as smoking, alcohol intake, physical activity, 
waist circumference or fasting glucose concentrations and family history of diabetes 
mainly in the large population-based in-house KORA F4 Study that had all this 
variables available and included only fasting participants. However, a further analysis 
was added adjusting for fasting glucose concentrations in 6 of the 8 cohorts that had 
fasting glucose concentrations available, and results remained highly consistent. Data 
on family history of diabetes besides the power issue might be moreover susceptible 
to inaccuracies. However, doing so, showed very similar results as in the presented 
main pooled analyses.  
Statistical concepts for risk reclassification such as categorical NRI have known 
limitations such as the arbitrary choice of risk categories if no recommended risk 
thresholds exist. Therefore, we also applied the continuous NRI that does not rely on 
predefined risk categories. Moreover, the result of the test on deviances was in line 
with the results of both NRI analyses. Thus, the model performance of afamin was 
consistent over all applied statistical concepts of risk prediction and discrimination. 
Marginal differences in NRI analyses when family history of diabetes was further added 
to the risk model were most probably caused by limited statistical power; however, the 
main conclusion drawn that afamin improved type 2 diabetes risk reclassification did 
not change. Moreover, as in most epidemiological studies, we cannot exclude that 
results are to some extent biased by residual and unmeasured confounding as well as 
loss-to-follow-up. Finally, the analyses were performed only in Caucasians and thus it 
has to be elucidated whether these findings can be replicated in other ethnicities.  
In summary, this large analysis of mainly population-based studies demonstrated 
that afamin is highly significantly associated with prediabetes, insulin resistance, 
prevalence of type 2 diabetes as well as the development of type 2 diabetes 
independent of major metabolic risk factors or parameters. Increased plasma afamin 
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concentrations may therefore indicate the development of type 2 diabetes already at a 
very early stage. As the number of individuals diagnosed with diabetes is steadily 
increasing since decades and according to the WHO global diabetes prevalence has 
doubled since 1980, finding crucial markers contributing to the development of type 2 
diabetes is indispensable for an adequate and rapid identification of affected patients 
or patients at high risk as well as for the elucidation of the pathogenesis of this disease. 
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Figures legends 
Figure 1: Forest plot illustrating the association of afamin with prevalent type 2 
diabetes (extended adjustment model), based on a random effects (RE) model for all 
8 studies as well as excluding KORA F3 and NPHSII since most participants in these 
studies were non-fasting. Panel A provides data for an afamin increment of 10 mg/L 
and panel B provides data for afamin divided into quartiles. Odds Ratios and 95% 
confidence intervals are shown for each study and the pooled analyses. Numbers for 
prevalent type 2 diabetes (yes / no) refer to the age- and sex-adjusted model. 
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Figure 2: Forest plot illustrating the association of afamin (increment 10 mg/L) with 
incident type 2 diabetes (extended adjustment model), based on a random effects (RE) 
model for all 8 studies as well as excluding KORA F3 and NPHSII. Panel A provides 
data for an afamin increment of 10 mg/L and panel B for afamin divided into quartiles. 
Odds Ratios and 95% confidence intervals are shown for each study and the pooled 
analyses. Numbers for incident type 2 diabetes (yes / no) refer to the age- and sex-
adjusted model. 
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Table 1: Pooled results from study-specific linear regression analyses of afamin (increment 10 mg/L) on type 
2 diabetes-related phenotypes at the baseline investigation excluding those with type 2 diabetes at baseline. 
 Adjustment for age and sex Extended adjustment 
Parameters / (n individuals) ß (95% CI) *, ‡ P ß (95% CI) †, ‡ P 
Ln-HbA1c (%) (n=7,828) § 0.006 (0.004-0.008) 4.41x10-10 0.003 (0.002-0.005) 3.09x10-4 
Ln-Insulin (µlU/ml) (n=13,156) || 0.172 (0.146-0.198) 3.32x10-39 0.101 (0.083-0.120) 1.51x10-26 
Ln-Glucose (mg/dL) (n=13,183) || 0.015 (0.010-0.020) 4.68x10-10 0.009 (0.006-0.013) 7.48x10-7 
Ln-HOMA-IR (n=13,153) || 0.187 (0.158-0.216) 3.00x10-36 0.110 (0.089-0.132) 1.37x10-23 
Ln-ISI(composite) (n=926) ¶ -0.246 (-0.278- -0.214) 2.18x10-50 -0.171 (-0.204- -0.137) 4.53x10-24 
N refer to the age- and sex-adjusted model; Ln refers to log-transformation based on the natural logarithm 
(ln). 
* Adjusted for age and sex; 
† Adjusted for age, sex, HDL cholesterol, triglycerides, BMI and hypertension 
‡ Meta-analysis beta estimate, 95% CI and P-values derived from a random effects model 
§ Studies included: Bruneck, SAPHIR, KORA F3, and KORA F4 
|| Studies included: Bruneck, SAPHIR, KORA F4, CoLaus, YFS, and FamHS 
¶ Study included: KORA F4 
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Table 2: Reclassification of individuals into low, medium and high risk categories for development of 
type 2 diabetes within the study period in the KORA F4 Study (median follow-up 6.4 years) when 
additionally considering afamin in the risk model. The baseline model includes the risk factors or 
parameters age, sex, HDL cholesterol, triglycerides, BMI, hypertension and glucose concentrations 
≥100 mg/dL (100-125 mg/dL vs. <100 mg/dL= reference). 
Individuals with incident type 2 diabetes (n=132) 
 Baseline model plus afamin 
Baseline model Total <5% risk 5-24% risk >=25% risk 
<5% risk 17 10 (58.8) 7 (41.2) * 0 (0.0) * 
5-24% risk 70 4 (5.7) † 49 (70.0) 17 (24.3) * 
>=25% risk 45 0 (0.0) † 5 (11.1) † 40 (88.9) 
Total 132 14 61 57 
* Moved to higher risk category which is correctly reclassified (light gray), n = 24; † Moved to lower 
risk category which is wrongly reclassified (dark gray), n = 9; stayed in the same risk category 
(medium grey), n=99; NRI 0.114 (95%CI 0.031-0.221), p=0.002. 
 
Individuals without incident type 2 diabetes (n=1,718) 
 Baseline model plus afamin 
Baseline model Total <5% risk 5-24% risk >=25% risk 
<5% risk 1,202 1,156 (96.2) 45 (3.7) † 1 (0.08) † 
5-24% risk 422 84 (19.9) * 310 (73.5) 28 (6.6) † 
>=25% risk 94 0 (0.0) * 26 (27.7) * 68 (72.3) 
Total 1,718 1,240 381 97 
* Moved to lower risk category which is correctly reclassified (light gray), n =110; † Moved to 
higher risk category which is wrongly reclassified (dark gray), n=74; stayed in the same risk 
category (medium grey); n =1534; NRI 0.021 (95%CI 0.006-0.036), p=0.008. 
Values are presented as n (row percent). 
Categorical net reclassification improvement (NRI) in this table is calculated for 132 individuals with 
and for 1,718 individuals without type 2 diabetes. Overall NRI for the total group: 0.135 (95%CI 
0.048-0.221), p=0.002. 
 
 
 
